https://vitasmlab.net

AVINMARK

Avian Influenza Targeted Library

Avian influenza viruses pose a major threat to global health due to their potential to spark pandemics. While primarily infect- ing birds, some strains like H5N1 and H7N9 can cross species barriers, causing severe human infections with high mortality rates (up to 60%). Their rapid mutation and reassortment capabilities raise concerns about adaptation for efficient human-to-human transmission, which could trigger devastating outbreaks. Current antivirals like neuraminidase inhibitors have limited efficacy against resistant strains, and vaccines require strain-specific development, leaving gaps in pandemic preparedness. Novel small molecular-based drugs targeting conserved viral proteins or host factors could provide broader protection across AIV subtypes. With H5N1 now spreading in mammals, the urgency for next-generation therapeutics has intensified—not just for human health, but to safeguard poultry industries and food security worldwide.



Example Targets:

Hemagglutinin Neuraminidase

RNA-Dependent RNA Polymerase

M2 Ion Channel Influenza Virus A Nucleoprotein



STK445497



STK769430



STL429331

Avian Influenza Targeted Library (AVINMARK) consists of compounds with potential antiviral activity, which were selected based on similarity to known modulators of Avian Influenza's proteins. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 1456 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.